What Ascaridil Treats: Main Uses and Benefits

Ascaridil is commonly used to help with acute or disruptive symptom patterns, such as those associated with parasitic infections. Its use is relevant across conditions involving certain distressing symptoms. The medicine is applied across domains where short-term symptomatic assistance is needed, and contributes to easing the overall symptom load during periods of heightened discomfort.

---

Easing Sudden or Intensifying Symptom Groups

This medicine may assist with symptom clusters that appear suddenly or fluctuate, often creating noticeable physiological strain or discomfort. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and contributes to improved day-to-day comfort during symptomatic periods. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns linked to organ-specific functional stress.

---

Supportive Management for Episodic Conditions

Ascaridil is relevant in contexts involving acute or unstable symptom patterns, such as those that appear in conditions characterized by periods of heightened symptoms and episodic manifestations. It is used during phases of increased distress or discomfort where short-term supportive symptom management is appropriate.

---

Quick Fact: May support with symptoms related to physiological strain.

Assisting Functional Stability

The medication is applied in addressing general clinical scenarios where symptoms may become temporarily overwhelming and interfere with routine activities. It assists with maintaining functional stability by offering supportive relief when symptoms create temporary functional strain or discomfort.

Regulatory References

1. European Medicines Agency (EMA) referral information

Official Eligibility Profile for Ascaridil (Levamisole)

The eligibility for Ascaridil is strictly defined by regulatory authorities and centers on patient health status and life stage.

Who Must Not Use This Medicine (Contraindications)

Use is strictly contraindicated for individuals who meet the following criteria:

• Known hypersensitivity or allergy to Levamisole hydrochloride or any component of the formulation.
• A history of or current pre-existing blood disorders (hematological abnormalities).

Restricted and Conditional Use

Regulatory labels state that Ascaridil should be used with caution and under restricted circumstances in patients with:

• Organ Impairment: Liver (hepatic) or kidney (renal) impairment. Use is explicitly not recommended for those with severe kidney diseases.
• Co-morbidities: Certain conditions, including epilepsy, rheumatoid arthritis, or Sjögren's syndrome.
• Drug Restrictions: Patients who have recently used or are scheduled to use organophosphorus compounds.

Age and Life Stage Status

The medicine is authorized for its primary use in both the adult and pediatric populations. However, use is not recommended for women who are pregnant or breastfeeding, due to a lack of adequate data to determine infant risk in these life stages.

The official regulatory documents for Ascaridil (Levamisole) define its interaction profile across three main categories: mandated timing rules, altered systemic exposure of co-administered medicines, and specific pharmacodynamic risks. The interaction structure is based strictly on documented outcomes and required administration constraints, without interpretation or therapeutic context.

Interacting Substance	Official Interaction Classification	Resulting Constraint or Outcome
Organophosphorus compounds	Contraindicated Combination	Must be separated by a 14-day period before or after Levamisole administration.
Alcohol (Ethanol)	Pharmacodynamic Risk	Causes a formal disulfiram-like reaction.
Phenytoin	Exposure Modification / Toxicity	Co-administration increases the toxicity of Phenytoin.
Ivermectin	Exposure Modification	Co-administration increases the systemic exposure of Ivermectin.
Albendazole	Exposure Modification	Co-administration decreases the systemic exposure of Albendazole's active metabolite.

Official interaction statements detail these constraints:

• Administration of Ascaridil is subject to a strict restriction requiring separation from Organophosphorus compounds by a mandatory 14-day window.
• Combining the medicine with Alcohol (Ethanol) is documented to result in a severe disulfiram-like reaction.
• Documented exposure alterations include the increase in Ivermectin bioavailability and the decrease in Albendazole active metabolite bioavailability when co-administered.
• Co-administration with Phenytoin may lead to increased Phenytoin toxicity.

How Ascaridil Works

Ascaridil (levamisole) acts via two primary mechanistic domains: a targeted action on parasitic neurology and a modulatory influence on the host's immune system.

---

Targeted Parasite Neuromuscular System

This mechanism describes the drug's direct influence on parasitic worms by targeting their nervous system. Ascaridil acts as an agonist at specific nicotinic acetylcholine receptors (nAChRs) on the worm's muscle cells, initiating continuous, intense nerve stimulation. This engagement within the cholinergic signaling pathway leads to a state of spastic paralysis which causes the loss of muscle tone required for adherence to the intestinal wall, facilitating the parasite's expulsion from the body.

---

Modulating Host Immune Pathways

This domain covers the drug's secondary mechanistic role in influencing activity within specific cellular components of the host immune system. Ascaridil engages mechanisms that modify activity within specific T-lymphocytes and macrophages. By subtly adjusting the signaling dynamics in these immunoregulatory pathways, the drug alters the host response profile and resulting physiological consequence.

Official Administration Protocols

Administration of Ascaridil relies on the oral route, defining how the medicine is taken by patients globally. As an oral medicine, the tablet is typically swallowed with a glass of liquid, such as water, milk, or juice. Official administration guidelines emphasize two distinct use patterns, each with its own frequency and duration.

---

Administration Schedule and Dosing

Usage Pattern	Adult Dose	Frequency and Duration
Curative (Anthelmintic)	150 mg as a single dose	Once only (short-term)
Chronic (Immunomodulator)	50 mg or 2.5 mg/kg	Administered on an alternate-day or intermittent cyclic schedule (prolonged duration)

---

Procedural Instructions for Intake

The tablet form of Ascaridil is intended to be swallowed whole and not chewed, consistent with standardized oral drug administration. However, the tablet may be crushed and mixed with a small amount of water or soft food if required for immediate consumption. For children, the dose is determined based on body weight, using the 2.5 mg/kg calculation for both the single curative dose and the alternate-day chronic regimen.

In the context of the prolonged, alternate-day schedule, managing adherence is crucial. If a dose is missed, official instructions state that the dose should be taken as soon as it is remembered, and the patient should then resume the original alternate-day pattern for subsequent doses.

Research Evidence / Overview of Studies for Ascaridil

---

Evidence for Use in Roundworm Infection (Ascariasis)

Ascaridil was studied for its use in roundworm infection, a condition associated with acute or disruptive episodes and marked by functional limitations. Research has focused on measuring changes in the parasitic load in the gut during the study period. The studies conducted during periods of increased symptom activity examined populations diagnosed with the large roundworm.

Research describes patterns related to physiological strain or stress that were monitored during the study period. Findings generally describe patterns related to changes in the presence of the parasite as observed in the study populations. However, results apply only to the populations studied, and findings describe group patterns, not personal outcomes.

Studies Comparing Ascaridil to Other Treatments

Some research has examined Ascaridil by comparing it to other medications available for roundworm infection. These comparative studies monitored outcomes related to physiological strain or stress and explored temporary physiological imbalance. The evidence is part of the research exploring symptom patterns, but comparative evidence is lacking in many areas. Follow-up durations were limited, and data for certain groups remain insufficient, meaning that the full picture of how Ascaridil compares to all alternatives is still emerging.

---

Evidence for Use in Pinworm Infection (Enterobiasis)

Ascaridil was studied for conditions characterized by fluctuating or episodic manifestations, including pinworm infection. Research has explored short-term symptom changes, with studies focusing on episodes where outcomes related to physical discomfort become more noticeable.

The research describes patterns related to changes in the parasite burden, which helps contextualize how patients reported their experience. Research has explored outcomes related to changes in the evidence of the parasite in the observed groups. However, certainty remains low regarding the full extent of its impact compared to other options, and results reflect the specific conditions under which the studies were conducted.

---

Long-term Studies and Follow-up

Research has also explored data related to post-study follow-up periods following the defined treatment period with Ascaridil. These studies monitored outcomes related to physiological strain or stress over defined time intervals and examined whether the patterns observed during treatment persisted.

Data for long-term outcomes for Ascaridil is still emerging, and follow-up durations were limited across many studies. The evidence is limited regarding sustained findings observed after the study period, and the long-term effects are not fully established. Therefore, there is limited information for how patients fare beyond the short to medium term after treatment.

---

Evidence in Special Populations

A limited number of studies examined specific populations, such as children, who may differ from the general adult population. These studies explored outcomes related to daily functioning or activity level in populations with varying symptom burdens.

Data for certain groups, including pregnant-related populations and those with certain comorbid conditions, remain insufficient. Evidence quality varies across studies, and sample sizes were modest in the research that focused on these specific subgroups. This means that subgroup findings are uncertain, and research provides context but not individual predictions about outcomes in these groups compared to the general population studied.

---

What is Still Uncertain About Ascaridil

The research conducted so far contributes to the broader evidence landscape, but some key questions remain open. Findings for Ascaridil vary across some studies, and evidence quality varies across studies, which may relate to consistency.

There is limited information for long-term outcomes, and comparative evidence is lacking against several current alternatives. The data are still emerging, and certainty remains low in areas related to treatment consistency across all populations. Studies help show what has been observed so far, but this evidence highlights what is known — and what is still uncertain — regarding Ascaridil.

Key Studies & References

1. PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections (Regulatory document related to post-market surveillance and long-term uncertainties)

Common questions about Ascaridil (FAQ)

---

Q: How is Ascaridil different from similar medicines used for the same condition?

The active ingredient in Ascaridil is described in official classifications as having a dual action.

It functions both as an Anthelmintic to target parasitic worms and as an Immunomodulator that can influence the host's immune system. This dual capacity is a characteristic noted in its official definition.

---

Q: Is Ascaridil available over the counter, or only with a prescription?

Regulatory authorities generally classify Ascaridil for human use as a prescription-only medicine.

This classification means the medicine is not available for retail purchase without a prescription.

---

Q: How quickly is Ascaridil expected to start working?

Studies and official product information indicate that the medicine is readily absorbed into the body.

Peak concentrations of the active ingredient in the bloodstream are typically reached within 1.5 to 2 hours following administration.

---

Q: How long does the effect of Ascaridil typically last after a dose?

Studies examining the body's processing of the medicine describe the drug's elimination half-life—the time it takes for half of the dose to leave the system—as typically being between 3 and 6 hours.

This figure is based on measurements of the parent drug's concentration.

---

Q: Is it necessary to finish the entire course of Ascaridil treatment?

Official patient counseling information advises that the full prescribed course of treatment be completed.

This is often noted even if symptoms begin to improve, as interrupting treatment may increase the possibility of a recurrent infection.

---

Q: Does Ascaridil cause drowsiness or affect alertness?

Regulatory documents list adverse reactions that affect the nervous system, including dizziness and somnolence (sleepiness).

The official product information generally includes precautions about performing activities that require full mental alertness if these effects are experienced.

---

Q: Do the side effects usually go away over time while taking Ascaridil?

Official documentation reports that some serious adverse effects, such as a severe drop in white blood cells (agranulocytosis), are considered to be spontaneously reversible once the medicine is discontinued.

Information regarding the typical duration and resolution of common, non-severe effects is not consistently addressed in regulatory summaries.

---

Q: What types of over-the-counter medicines might interact with Ascaridil?

Official interaction information indicates Ascaridil can interact with a wide variety of medicines, including some non-prescription products.

The drug's profile is listed as having major or moderate interaction potential with over 180 substances, highlighting the need to review the interaction status of all co-administered products.

---

Q: Are there any specific foods or supplements that official sources suggest avoiding when taking Ascaridil?

Official documentation strictly states that the use of Ascaridil with alcohol (ethanol) can result in a severe disulfiram-like reaction.

This is the only mandatory constraint of this type specifically highlighted in the product's official interaction profile. No other specific foods or supplements are explicitly mentioned as mandatory constraints.

---

Q: Does Ascaridil interact with common medications like blood thinners or diabetes drugs?

Literature reports a significant interaction between Ascaridil and the blood thinner warfarin when used in a certain chemotherapy regimen.

This interaction was observed to increase the blood's clotting time (International Normalized Ratio or INR).

---

Q: Where can I find the official regulatory research evidence for Ascaridil?

Regulatory data and supporting research evidence for the active ingredient are publicly referenced through government resources.

These sources include portals from the National Institutes of Health (NIH), as well as official FDA labeling archives and EMA drug information summaries.

---

Q: How long has Ascaridil been approved by major regulatory bodies?

The active ingredient in Ascaridil has a long history, dating back to its first use as an anti-worm agent in 1969.

It was later formally approved by the FDA in 1990 as an adjuvant treatment for a type of cancer.

---

Q: Does Ascaridil have any 'Black Box' or major warnings from regulatory agencies?

Official regulatory information for the active ingredient includes prominent warnings about rare but serious adverse reactions.

These include the potential for severe hematologic toxicity (Agranulocytosis) and neurological events officially linked to cumulative or prolonged exposure.

---

Q: Is Ascaridil considered a controlled substance?

Regulatory classifications indicate that the active ingredient in Ascaridil is not designated as a controlled substance under the Controlled Substances Act (CSA) in the United States.

---

Q: Why do I need a prescription for Ascaridil?

The regulatory decision to classify Ascaridil as prescription-only is connected to its safety profile.

This profile includes the potential for rare but serious adverse effects, indicating that specialized use conditions and monitoring may be necessary to manage risk.

---

Q: What general information exists about how Ascaridil is cleared from the body?

Studies indicate that the medicine is primarily processed, or metabolized, in the liver.

It is then predominantly eliminated from the body via the kidneys and is passed out in the urine.

---

Q: Why is Ascaridil sometimes mentioned in public health discussions or news reports?

The active ingredient has been the subject of public health discussions because it has been documented for its use as an adulterant in illegal substances.

This is reported to lead to cases of severe hematologic and nervous system complications in individuals who consume the adulterated street drugs.

---

Q: Is Ascaridil known by any other names internationally?

The active ingredient in Ascaridil is known globally under various international trade names.

Examples of these names include Ketrax, Ergamisol, and Elmisol, reflecting different pharmaceutical presentations worldwide.

---

Q: Why do health professionals stress compliance with the Ascaridil regimen?

Official safety documentation notes that compliance with the prescribed regimen is important, particularly in chronic use patterns.

Official safety information connects serious adverse reactions, such as severe hematologic toxicity, to the medicine's cumulative dose and prolonged or repeated exposure.

Official Storage Requirements

Ascaridil must be stored in accordance with official regulatory requirements to ensure its stability. The product should be kept in a cool location, away from heat and sources of ignition, and the container must remain tightly sealed [Source: Regulatory Safety Data Sheets (SDS)]. To maintain chemical integrity, the medicine must not be stored with strong oxidizing agents.

Access, Handling, and Waste

For safety, the product is required to be stored locked up (P405) to prevent unauthorized access. Handling procedures dictate that users wash thoroughly after handling and avoid breathing dust from the product. Disposal of the medicine and container must strictly adhere to national/international regulations (P501), utilizing an approved waste disposal plant to avoid release to the environment.